STUDY NAME: The DOPPLER-CIP Trial
SESSION NAME: Hot Line I – Acute myocardial infarction
In patients with chronic ischemic heart disease, a small left ventricle with thick walls, is the strongest predictor of morphologic remodelling, which is generally considered a first step towards heart failure, according to unexpected findings presented today at ESC Congress 2015.
Results of the DOPPLER-CIP (which stands for “Determining Optimal non-invasive Parameters for the Prediction of Left vEntricular morphologic and functional Remodeling in Chronic Ischemic Patients”) study were not expected and, if confirmed by other studies, “could completely change risk stratification among patients with stable coronary artery disease,” according to the study coordinators Frank Rademakers, MD and Jan D’Hooge, PhD.
“We were indeed surprised by these findings,” said the investigators, who are from the University of Leuven, Belgium. “The general belief is that larger ventricles with thin walls (a typical ‘infarct ventricle’) would be at higher risk of remodelling, with a possible explanation for this being that there is increased wall stress in such hearts. But out findings show that it is actually small hearts with thick walls that are more at risk. As this goes against general belief, we have checked and re-checked our data, and analysis, and have run several consistency tests, but they all led to this same conclusion.”
There are currently no guidelines for assessing a patient’s risk for this type of deterioration, they noted.
DOPPLER-CIP compared different non-invasive methods to determine the most useful tool at baseline for predicting risk of cardiac remodelling two years later.
The study included 676 patients, from 6 European countries, with suspicion of chronic ischemic heart disease.
The patients underwent standard diagnostic tests at baseline including: electrocardiogram (ECG), exercise testing with continuous ECG monitoring, and measurement of maximal oxygen uptake (VO2max), as well as blood sampling and quality of life assessments. In addition to these standard tests, patients also underwent at least two stress imaging tests including echocardiography (ECHO), magnetic resonance imaging (MRI) and/or single positron emission computed tomography (SPECT) stress test, stress ECHO and stress MRI.
After these baseline evaluations all patients received optimal, guideline-based treatment including revascularization, partial revascularization, or pharmacologic treatment at their physician’s discretion.
At the end of the study period, about 20% of the subjects had evidence of cardiac remodelling based on MRI or ECHO results, with the best baseline predictors of this remodelling being left ventricular size measured as the “left ventricular end-diastolic volume” (LV EDV) and left ventricular mass (LVM).
Specifically, a small LV end-diastolic volume (< 145 ml ) at baseline had a 25-40% chance of remodelling, compared to a larger EDV which had a decreased risk (20%; P<0.001) with risk also increasing with increasing wall thickness. (P=0.003).
“By identifying baseline LV EDV and LVM – measurements that can easily be assessed with standard imaging – as the best predictors of future remodelling and potentially heart failure risk, our study could guide clinicians away from more expensive tests for risk assessment,” they said.
Notes to editor
SOURCES OF FUNDING: The study was funded by the EU (FP7) framework program (DOPPLER-CIP; grant number 223615). Logistical support (software tools for data analysis) was provided by by Philips Healthcare, GE Healthcare, TomTec Imaging Systems, MedViso and Bracco Imaging.
DISCLOSURES: Dr. D’Hooge disclosed research funding from Philips, research contracts with GE, and a collaboration with MedViso. Professor Rademakers had no disclosures.
ESC Press Office
For background information or assistance, please contact the ESC Press Office.
For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2015
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at email@example.com.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.